CD33 inhib 
Welcome,         Profile    Billing    Logout  
 13 Companies  15 Products   15 Products   46 Diseases   8 Trials   489 News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BI 836858 / Boehringer Ingelheim
Beat AML, NCT03013998: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from Beat AML trial for acute myeloid leukemia
Recruiting
1/2
2000
US
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Enasidenib, Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), GS-9973, ENTO, Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), TAK-924, MLN4924, Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21)
Beat AML, LLC
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
12/26
12/26
vixtimotamab (AMV564) / Affimed
NCT04128423: Study of AMV564 in Subjects With Advanced Solid Tumors

Active, not recruiting
1
65
US
AMV564
Amphivena Therapeutics, Inc.
Locally Advanced or Metastatic Solid Tumors
12/21
12/21
CC-96191 / BMS
NCT04789655: Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1
80
Europe, Canada, US
CC-96191
Celgene
Leukemia, Myeloid
02/25
02/25
huCD33-BsAb / Y-mAbs Therap
NCT05077423: A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated
1
3
US
CD33*CD3 BsAb, CD33xCD3
Y-mAbs Therapeutics, Children's Oncology Group
AML, Childhood
12/22
12/22
GTB-3650 / GT Biopharma
NCT06594445: HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Recruiting
1
45
US
GTB-360, anti-CD16/IL-15/anti-CD33
Masonic Cancer Center, University of Minnesota
Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
11/28
11/29
IBR733 / Imbioray Bio
NCT05215015: Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia

Recruiting
1
18
RoW
Anti-CD33/CLL1 CAR-NK Cells
Wuxi People's Hospital, Imbioray (Hangzhou) Biomedicine Co., Ltd.
Acute Myeloid Leukemia
11/22
11/22
NCT06234904: Study of IBR733 Cell Injection in Acute Myeloid Leukemia

Not yet recruiting
1
18
RoW
IBR733 Cell Injection
Imbioray (Hangzhou) Biomedicine Co., Ltd., The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
02/25
08/25
QN-023a / Qihan Biotech
NCT05665075: Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

Recruiting
1
19
RoW
QN-023a, Cyclophosphamid, Fludarabine, Cytarabine, VP-16
Zhejiang University, Hangzhou Qihan Biotech Co.,Ltd.
AML, Adult
12/23
12/25
NCT05601466: Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

Terminated
1
3
RoW
QN-023a, Cyclophosphamid, Fludarabine, Cytarabine
Institute of Hematology & Blood Diseases Hospital, China, Hangzhou Qihan Biotech Co.,Ltd.
AML, Adult
04/23
04/23

Download Options